Lead sponsor
Carmot Therapeutics, Inc.
7 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.
7
Trials led
1
Active
1,236
Total enrollment
122
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 1
3
Phase 2
4
Trials by status
Active, not recruiting
1
Completed
6
Trials led
TrialKey I/E criterionPhaseStatusEnrollment
A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related ComorbidityBMI 27-30Ph 2Completed469
A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes MellitusBMI ≥25Ph 2Active, not recruiting360
A Study of CT-388 in Otherwise Healthy Overweight and Obese Adults and Patients With Type 2 Diabetes MellitusBMI 27-40Ph 1Completed129
A Study of CT-868 in Overweight and Obese Participants With Type 2 Diabetes MellitusBMI ≥27Ph 2Completed103